<unk>  is used in adults with transfusion dependent beta thalassemia and was shown to reduce transfusion burden by 33% compared to placebo as well as reducing serum ferritin (storage iron) concentrations. But the medication had no significant effect with regards to decreasing liver or heart iron concentrations. Possible adverse effects include temporary bone pain, joint pains (arthralgias), dizziness, elevated blood pressure (hypertension) and elevated uric acid levels (hyperuricemia). There was also an increased risk of thrombosis (blood clots) in patients who have risk factors for thrombosis who are taking<unk> .<unk>  is currently being evaluated for use in adults with non-transfusion dependent beta thalassemia.
Luspatercept
Teprotumumab
Bezlotoxumab
Dostarlimab
Sacituzumab govitecan
Trafermin
Lestaurtinib
Tralokinumab